ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2019-1-60-75ssmu-2171Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESМоноциты при злокачественных новообразованиях: перспективы и точки приложения для диагностики и терапииMonocytes and cancer: promising role as a diagnostic marker and application in therapyhttps://orcid.org/0000-0003-2865-7576ПатышеваМ. Р.PatyshevaM. R.

Патышева Марина Ринатовна, врач-лаборант, лаборатория молекулярной онкологии и иммунологии, НИИ онкологии

Научно-исследовательский институт (НИИ) онкологии

634009, г. Томск, пер. Кооперативный, 5

Patysheva Marina R., Junior Researcher, Cancer Research Institute

Cancer Research Institute

5, Kooperativny Str., Tomsk, 634050

starin5@yandex.ruСтахееваМ. Н.StakheevaM. N.

Стахеева Марина Николаевна, доктор медицинских наук, ведущий научный сотрудник, лаборатория молекулярной онкологии и иммунологии, НИИ онкологии, Томский НИМЦ; старший научный сотрудник, лаборатория трансляционной клеточной и молекулярной биомедицины, НИ ТГУ; старший научный сотрудник, НИ ТПУ

634009, г. Томск, пер. Кооперативный, 5, 

634050, г. Томск, пр. Ленина, 36, 

634009, г. Томск, пр. Ленина, 30

Stakheeva Marina N., DM, Senior Researcher, Cancer Research Institute, Tomsk NRMC, RAS

5, Kooperativny Str., Tomsk, 634050, 

36, Lenin Str., Tomsk, 634050, 

30, Lenin Str., Tomsk, 634050

https://orcid.org/0000-0001-5758-7330ЛарионоваИ. В.LarionovaI. V.

Ларионова Ирина Валерьевна, младший научный сотрудник, лаборатория трансляционной клеточной и молекулярной биомедицины, НИ ТГУ; аспирант, Томский НИМЦ Научно-исследовательский институт (НИИ) онкологии

634009, г. Томск, пер. Кооперативный, 5, 

634050, г. Томск, пр. Ленина, 36

Larionova Irina V., Junior Researcher, Laboratory of Тranslational Сellular and Molecular Вiomedicine, NR TSU, Post-Graduate Student, Cancer Research Institute, Tomsk NRMC, RAS

5, Kooperativny Str., Tomsk, 634050, 

36, Lenin Str., Tomsk, 634050

https://orcid.org/0000-0003-1630-4466ТарабановскаяН. А.TarabanovskayaN. A.

Тарабановская Наталья Анатольевна, кандидат медицинских наук, научный сотрудник, отделение общей онкологии, НИИ онкологии

Научно-исследовательский институт (НИИ) онкологии

634009, г. Томск, пер. Кооперативный, 5

Tarabanovskaya Natalia А., PhD, Researcher, Cancer Research Institute,. Tomsk NRMC, RAS

5, Kooperativny Str., Tomsk, 634050

https://orcid.org/0000-0003-4671-6306ГригорьеваЕ. С.GrigorievaE. S.

Григорьева Евгения Сергеевна, кандидат медицинских наук, мл. научный сотрудник, лаборатория молекулярной онкологии и иммунологии, НИИ онкологии, Томский НИМЦ; старший научный сотрудник, лаборатория трансляционной клеточной и молекулярной биомедицины, НИ ТГУ

634009, г. Томск, пер. Кооперативный, 5, 

634050, г. Томск, пр. Ленина, 36

Grigorieva Evgenia S., PhD, Junior Researcher, Cancer Research Institute, Tomsk NRMC, RAS; Researcher, Laboratory of Тranslational Сellular and Molecular Вiomedicine, NR TSU

5, Kooperativny Str., Tomsk, 634050, 

36, Lenin Str., Tomsk, 634050

https://orcid.org/0000-0003-4382-5697СлонимскаяЕ. М.SlonimskayaE. M.

Слонимская Елена Михайловна, доктор медицинских наук, профессор кафедра общей онкологии, СибГМУ; заведующая отделением общей онкологии, НИИ онкологии, Томский НИМЦ

634009, г. Томск, пер. Кооперативный, 5, 

634050, г. Томск, Московский тракт, 2

Slonimskaya Elena М., DM, Professor, Head of the General Oncology, Cancer Research Institute, Tomsk NRMC, RAS

5, Kooperativny Str., Tomsk, 634050 

2, Mosсow Trakt, Tomsk, 634050

https://orcid.org/0000-0003-0898-3075КжышковскаЮ. Г.KzhyshkowskaJ. G.

Кжышковска Юлия Георгиевна, доктор биологических наук, профессор, заведующий лабораторией трансляционной клеточной и молекулярной биомедицины, НИ ТГУ; заведующий отделом врожденного иммунитета и толерантности, Институт трансфузионной медицины и иммунологии, Университет Гейдельберга

634050, г. Томск, пр. Ленина, 36, 

68167, г. Маннхайм, Theodor-Kutzer-Ufer, 1-3

Kzhyshkowska Julia G., DBS, Professor, Head of the Laboratory Тranslational Сellular and Molecular Вiomedicine, NR TSU;The Head of the Department of Innate Immunity and Tolerance, Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, University of Heidelberg

36, Lenin Str., Tomsk, 634050, 

1-3, Theodor-Kutzer-Ufer Mannheim, 68167

https://orcid.org/0000-0003-1526-9013ЧердынцеваН. В.CherdyntsevaN. V.

Чердынцева Надежда Викторовна, доктор биологических наук, профессор, член-корреспондент РАН, зав. лабораторией молекулярной онкологии и иммунологии, НИИ онкологии, Томский НИМЦ; ведущий научный сотрудник, лаборатория трансляционной клеточной и молекулярной биомедицины, НИ ТГУ

634009, г. Томск, пер. Кооперативный, 5, 

634050, г. Томск, пр. Ленина, 36

Cherdyntseva Nadezhda V., DBS, Professor, Corresponding Мember of RAS, Head of the Laboratory of Molecular Оncology and Immunology, Cancer Research Institute, Tomsk NRMC, RAS; Senior Researcher, Laboratory of Тranslational ellular and Мolecular Вiomedicine, NR TSU

5, Kooperativny Str., Tomsk, 634050, 

36, Lenin Str., Tomsk, 634050

Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук (РАН)РоссияTomsk National Research Medical Center (NRMC) of the Russian Academy of Sciences (RAS)Russian FederationТомский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук (РАН); Национальный исследовательский Томский государственный университет (НИ ТГУ); Национальный исследовательский Томский политехнический университет (НИ ТПУ)РоссияTomsk National Research Medical Center (NRMC) of the Russian Academy of Sciences (RAS); National Research Tomsk State University (NR TSU); National Research Tomsk Polytechnic University (NR TPU)Russian FederationТомский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук (РАН); Национальный исследовательский Томский государственный университет (НИ ТГУ)РоссияTomsk National Research Medical Center (NRMC) of the Russian Academy of Sciences (RAS); National Research Tomsk State University (NR TSU)Russian FederationТомский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук (РАН); Сибирский государственный медицинский университет (СибГМУ)РоссияTomsk National Research Medical Center (NRMC) of the Russian Academy of Sciences (RAS); Siberian State Medical University (SSMU)Russian FederationНациональный исследовательский Томский государственный университет (НИ ТГУ); Университет ГейдельбергаРоссияNational Research Tomsk State University (NR TSU); University of HeidelbergRussian Federation2019160520191816075Copyright © Патышева М.Р., Стахеева М.Н., Ларионова И.В., Тарабановская Н.А., Григорьева Е.С., Слонимская Е.М., Кжышковска Ю.Г., Чердынцева Н.В., 20192019Патышева М.Р., Стахеева М.Н., Ларионова И.В., Тарабановская Н.А., Григорьева Е.С., Слонимская Е.М., Кжышковска Ю.Г., Чердынцева Н.В.Patysheva M.R., Stakheeva M.N., Larionova I.V., Tarabanovskaya N.A., Grigorieva E.S., Slonimskaya E.M., Kzhyshkowska J.G., Cherdyntseva N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/2171

В процесс взаимодействия злокачественного новообразования и иммунной системы вовлечены эффекторы как адаптивного, так и врожденного звена иммунитета. Моноциты являются участниками неспецифической иммунной реакции и опосредуют свою основную функцию через пополнение пула опухолеассоциированных макрофагов, дендритных клеток и супрессорных клеток миелоидного происхождения, которые регулируют взаимоотношения инфильтрирующих опухоль-иммунокомпетентных клеток с опухолевыми клетками и с другими компонентами микроокружения, а также пролиферацию опухолевых клеток, ангиогенез, процессы диссеминации. Моноциты, будучи непосредственными участниками персистирующего воспаления, вовлекаются в реализацию его модулирующего воздействия на процесс развития опухоли. Изучение молекулярных механизмов рекрутирования и дифференцировки моноцитов при злокачественных новообразованиях представляется перспективным направлением как с диагностической целью, так и в плане поиска таргетных молекул для управления макрофагами и дендритными клетками опухолевого микроокружения. В обзоре дана характеристика моноцитов периферической крови с учетом гетерогенности их популяции. Описаны значимые при онкологических заболеваниях Tie2+ и поляризованные по фенотипу макрофагов моноциты CD163+ и CD204+, а также ассоциированные с раком макрофагоподобные клетки (circulation cancer associated macrophage-like cells, CAMLs). Показано вовлечение субпопуляций моноцитов в патогенез онкологических заболеваний разных локализаций на этапах формирования предшественников моноцитов в костном мозге, циркуляции в периферической крови и дифференцировки в ткани опухоли.

 Interrelationship between a malignant tumor and the immunity are provided by the involvement of both adaptive and innate immune systems. Monocytes are major participants in nonspecific immune response and mediate their key function through refilling the pool of tumor-associated macrophages, dendritic cells and myeloid suppressor cells. All these populations regulate the relationship of tumor-infiltrating immunocompetent cells with tumor cells and with other components of the microenvironment, as well as tumor cell proliferation, angiogenesis, and dissemination. Monocytes, being direct participants of the chronic persistent inflammation, are involved in the inflammation impact on both tumor origin and progression. The study of the molecular mechanisms of monocyte recruitment and differentiation in malignant neoplasms seems to be a promising direction, both for a diagnostic purpose and as a search for targeting molecules for the control of macrophages and dendritic cells in the tumor microenvironment. In this review, the characteristics of peripheral blood monocytes are given, taking into account the heterogeneity of their population. Tie2+ cells and macrophage-polarized CD163+ and CD204+ -monocytes, as well as cancer-associated macrophage-like cells (CAMLs), are described as contributors to cancer disease progression and outcome. The involvement of monocyte subpopulations in the pathogenesis of oncological diseases of different localizations at the stages of the formation of monocyte precursors in the bone marrow, circulation in peripheral blood and differentiation in tumor tissue is shown.

иммуноонкологиясубпопуляции моноцитовдиагностикапрогнозиммунотерапия ракаimmuno-oncologymonocyte subpopulationsprognosiscancer immunotherapyГрантами РФФИ № 17-29-06037, РНФ № 14-15-00350Grants No. 17-29-06037, RNF No. 14-15-00350ReferencesWilliams M.J. Drosophila hemopoiesis and cellular immunity. J. Immunol. 2007; 178 (8): 4711–4716. DOI: 10.4049/jimmunol.178.8.4711.Williams M.J. Drosophila hemopoiesis and cellular immunity. J. Immunol. 2007; 178 (8): 4711–4716. DOI: 10.4049/jimmunol.178.8.4711.Ziegler-Heitbrock L. Blood monocytes and their subsets: established features and open questions. Frontiers in Immunology. 2015; 6: 423. DOI: 10.3389/fimmu.2015.00423.Ziegler-Heitbrock L. Blood monocytes and their subsets: established features and open questions. Frontiers in Immunology. 2015; 6: 423. DOI: 10.3389/fimmu.2015.00423.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–455. DOI: 10.1038/nature12034.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–455. DOI: 10.1038/nature12034.Kzhyshkowska J., Gudima A., Moganti K., Gratchev A., Orekhov A. Perspectives for monocyte/macrophage-based diagnostics of chronic inflammation. Transfus. Med. Hemother. 2016; 43 (2): 66–77. DOI: 10.1159/000444943.Kzhyshkowska J., Gudima A., Moganti K., Gratchev A., Orekhov A. Perspectives for monocyte/macrophage-based diagnostics of chronic inflammation. Transfus. Med. Hemother. 2016; 43 (2): 66–77. DOI: 10.1159/000444943.Mosig S., Rennert K., Krause S., Kzhyshkowska J., Neunü- bel K., Heller R., Funke H. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. Fasber J. 2009; 23 (3): 866–874. DOI: 10.1096/fj.08-118240.Mosig S., Rennert K., Krause S., Kzhyshkowska J., Neunü- bel K., Heller R., Funke H. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. Fasber J. 2009; 23 (3): 866–874. DOI: 10.1096/fj.08-118240.Hristov M. Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb. Haemost. 2011; 106 (5): 757–762. DOI: 10.1160/TH11-07-0500.Hristov M. Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb. Haemost. 2011; 106 (5): 757–762. DOI: 10.1160/TH11-07-0500.Grivennikov S. and Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 2010; February; 20 (1): 65. DOI: 10.1016/j.gde.2009.11.004.Grivennikov S. and Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 2010; February; 20 (1): 65. DOI: 10.1016/j.gde.2009.11.004.Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 2011; 8 (3): 151–160. DOI: 10.1038/nrclinonc.2010.223.Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 2011; 8 (3): 151–160. DOI: 10.1038/nrclinonc.2010.223.Таширева Л.А., Перельмутер В.М., Манских В.Н., Денисов Е.В., Савельева О.Е., Кайгородова Е.В., Завьялова М.В. Типы иммуновоспалительных реакций как алгоритмы взаимодействия клеток в условиях репаративной регенерации и опухолевого роста. Биохимия. 2017; 82 (5): 542–555. DOI: 10.1134/s0006297917050029.Tashireva L. A, Perelmuter. V.M., Manskikh V.N., Denisov E.V., Savelieva O.E., Kaygorodova E.V., Zavyalova M.V. Types of immune inflammatory responses as a reflection of cell-cell interactions in tissue regeneration and tumor growth – Biochemistry. 2017; 82 (5): 542–555 (in Russ.). DOI: 10.1134/s0006297917050029.Stakheyeva M., Riabov V., Mitrofanova I., Litviakov N., Choynzonov E., Cherdyntseva N., Kzhyshkowska J. Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy. Curr. Pharm. Des. 2017; 23: 32. DOI: 10.2174/1381612823666170714161703.Stakheyeva M., Riabov V., Mitrofanova I., Litviakov N., Choynzonov E., Cherdyntseva N., Kzhyshkowska J. Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy. Curr. Pharm. Des. 2017; 23: 32. DOI: 10.2174/1381612823666170714161703.Buldakov M., Zavyalova M., Krakhmal N., Telegina N., Vtorushin S., Mitrofanova I., Riabov V., Yin S., Song B., Cherdyntseva N., Kzhyshkowska J. CD68+, but not stabilin-1+ tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiology. 2017; 222 (1): 31–38. DOI: 10.1016/j.imbio.2015.09.011.Buldakov M., Zavyalova M., Krakhmal N., Telegina N., Vtorushin S., Mitrofanova I., Riabov V., Yin S., Song B., Cherdyntseva N., Kzhyshkowska J. CD68+, but not stabilin-1+ tumor associated macrophages in gaps of ductal tumor structures negatively correlate with the lymphatic metastasis in human breast cancer. Immunobiology. 2017; 222 (1): 31–38. DOI: 10.1016/j.imbio.2015.09.011.Little M.C., Hurst R.J., Else K.J. Dynamic changes in macrophage activation and proliferation during the development and resolution of intestinal inflammation. J. Immunol. 2014; 193 (9): 4684–4695. DOI: 10.4049/jimmunol.1400502.Little M.C., Hurst R.J., Else K.J. Dynamic changes in macrophage activation and proliferation during the development and resolution of intestinal inflammation. J. Immunol. 2014; 193 (9): 4684–4695. DOI: 10.4049/jimmunol.1400502.Waskow C., Liu K., Darrasse-Jeze G., Guermonprez P., Ginhoux F. The receptor tyrosine kinase Flt3 is re quired for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 2008; 9 (6): 676–683. DOI: 10.1038/ni.1615.Waskow C., Liu K., Darrasse-Jeze G., Guermonprez P., Ginhoux F. The receptor tyrosine kinase Flt3 is re quired for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 2008; 9 (6): 676–683. DOI: 10.1038/ni.1615.Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., Cyster J.G. Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity. 2005; 22 (4): 439–450. DOI: 10.1016/j.immuni.2005.02.007.Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., Cyster J.G. Intrinsic lymphotoxin-β receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity. 2005; 22 (4): 439–450. DOI: 10.1016/j.immuni.2005.02.007.Iwasaki H., Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity. 2007; 26 (6): 726–740. DOI: 10.1016/j.immuni.2007.06.004.Iwasaki H., Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity. 2007; 26 (6): 726–740. DOI: 10.1016/j.immuni.2007.06.004.Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nature Reviews Immunology. 2011; 11 (11): 750–761. DOI: 10.1038/nri3088.Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nature Reviews Immunology. 2011; 11 (11): 750–761. DOI: 10.1038/nri3088.Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., Ryan R.J., Iwamoto Y., Marinelli B., Gorbatov R., Forghani R., Novobrantseva T.I., Koteliansky V., Figueiredo J.L., Chen J.W., Anderson D.G., Nahrendorf M., Swirski F.K., Weissleder R., Pittet M.J. Origins of tumor-associated macrophages and neutrophils. Proceedings of the National Academy of Sciences. 2012; 109 (7): 2491–2496. DOI: 10.1073/pnas.1113744109.Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., Ryan R.J., Iwamoto Y., Marinelli B., Gorbatov R., Forghani R., Novobrantseva T.I., Koteliansky V., Figueiredo J.L., Chen J.W., Anderson D.G., Nahrendorf M., Swirski F.K., Weissleder R., Pittet M.J. Origins of tumor-associated macrophages and neutrophils. Proceedings of the National Academy of Sciences. 2012; 109 (7): 2491–2496. DOI: 10.1073/pnas.1113744109.Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141 (1): 39–51. DOI: 10.1016/j.cell.2010.03.014.Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141 (1): 39–51. DOI: 10.1016/j.cell.2010.03.014.Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schäfer R., Stanley E.R., Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004; 64 (15): 5378–5384. DOI: 10.1158/0008-5472.Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schäfer R., Stanley E.R., Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 2004; 64 (15): 5378–5384. DOI: 10.1158/0008-5472.Paulus P., Stanley E.R., Schafer R., Abraham D., Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006; 66 (8): 4349–4356. DOI: 10.1158/0008-5472.CAN-05-3523.Paulus P., Stanley E.R., Schafer R., Abraham D., Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006; 66 (8): 4349–4356. DOI: 10.1158/0008-5472.CAN-05-3523.De Nardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirstrom K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1 (1): 54–67. DOI: 10.1158/2159-8274.CD-10-0028.De Nardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirstrom K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1 (1): 54–67. DOI: 10.1158/2159-8274.CD-10-0028.Schmeler K.M., Vadhan-Raj S., Ramirez P.T., Apte S.M., Cohen L., Bassett R.L., Iyer R.B., Wolf J.K., Levenback C.L., Gershenson D.M., Freedman R.S. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009; 113 (2): 210–215. DOI: 10.1016/j.ygyno.2009.02.007.Schmeler K.M., Vadhan-Raj S., Ramirez P.T., Apte S.M., Cohen L., Bassett R.L., Iyer R.B., Wolf J.K., Levenback C.L., Gershenson D.M., Freedman R.S. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009; 113 (2): 210–215. DOI: 10.1016/j.ygyno.2009.02.007.Spitler L.E., Grossbard M.L., Ernstoff M.S., Silver G., Jacobs M., Hayes F.A., Soong S.J. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 2000; 18 (8): 1614–1621. DOI: 10.1200/JCO.2000.18.8.1614.Spitler L.E., Grossbard M.L., Ernstoff M.S., Silver G., Jacobs M., Hayes F.A., Soong S.J. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 2000; 18 (8): 1614–1621. DOI: 10.1200/JCO.2000.18.8.1614.Pinedo H.M., Buter J., Luykx de Bakker S.A., Pohlmann P.R., van Hensbergen Y., Heideman D.A., van Diest P.J., de Gruijl T.D., van der Wall E. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur. J. Cancer. 2003; 39 (8): 1061– 1067. DOI: 10.1016/s0959-8049(03)00131-x.Pinedo H.M., Buter J., Luykx de Bakker S.A., Pohlmann P.R., van Hensbergen Y., Heideman D.A., van Diest P.J., de Gruijl T.D., van der Wall E. Extended neoadjuvant chemotherapy in locally advanced breast cancer combined with GM-CSF: effect on tumour-draining lymph node dendritic cells. Eur. J. Cancer. 2003; 39 (8): 1061– 1067. DOI: 10.1016/s0959-8049(03)00131-x.Jaipersad A.S., Lip G.Y., Silverman S., Shantsila E. The Role of Monocytes in Angiogenesis and Atherosclerosis. Journal of the American College of Cardiology. 2014; 63 (1): 1–11. DOI: 10.1016/j.jacc.2013.09.019.Jaipersad A.S., Lip G.Y., Silverman S., Shantsila E. The Role of Monocytes in Angiogenesis and Atherosclerosis. Journal of the American College of Cardiology. 2014; 63 (1): 1–11. DOI: 10.1016/j.jacc.2013.09.019.Srivastava M., Jung S., Wilhelm J., Fink L., Bьhling F., Welte T., Bohle R.M., Seeger W., Lohmeyer J., Maus U.A. The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J. Immunol. 2005; 175 (3): 1884–1893. DOI: 10.4049/jimmunol.175.3.1884.Srivastava M., Jung S., Wilhelm J., Fink L., Bьhling F., Welte T., Bohle R.M., Seeger W., Lohmeyer J., Maus U.A. The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles. J. Immunol. 2005; 175 (3): 1884–1893. DOI: 10.4049/jimmunol.175.3.1884.Thomas-Ecker S., Lindecke A., Hatzmann W., Kaltschmidt C., Zänker K.S., Dittmar T. Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells. Proceedings of the National Academy of Sciences. 2007; 104 (13): 5539–5544. DOI: 10.1073/pnas.0700732104.Thomas-Ecker S., Lindecke A., Hatzmann W., Kaltschmidt C., Zänker K.S., Dittmar T. Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells. Proceedings of the National Academy of Sciences. 2007; 104 (13): 5539–5544. DOI: 10.1073/pnas.0700732104.Gerhardt T., Ley K. Monocyte trafficking across the vessel wall. Cardiovasc. Res. 2015; 107 (3): 321–330. DOI: 10.1093/cvr/cvv147.Gerhardt T., Ley K. Monocyte trafficking across the vessel wall. Cardiovasc. Res. 2015; 107 (3): 321–330. DOI: 10.1093/cvr/cvv147.Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein 1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000; 6 (8): 3282–3289.Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein 1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000; 6 (8): 3282–3289.Lebrecht A., Grimm C., Lantzsch T., Ludwig E., Hefler L., Ulbrich E. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004; 25 (1–2): 14–17. DOI: 10.1159/000077718.Lebrecht A., Grimm C., Lantzsch T., Ludwig E., Hefler L., Ulbrich E. Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol. 2004; 25 (1–2): 14–17. DOI: 10.1159/000077718.Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475 (7355): 222–225. DOI: 10.1038/nature10138.Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475 (7355): 222–225. DOI: 10.1038/nature10138.Groblewska M., Mroczko B., Wereszczyńska-Siemiatkowska U., Myśliwiec P., Kedra B., Szmitkowski M. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin. Chem. Lab. Med. 2007; 45 (1): 30–34. DOI: 10.1515/CCLM.2007.025.Groblewska M., Mroczko B., Wereszczyńska-Siemiatkowska U., Myśliwiec P., Kedra B., Szmitkowski M. Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients. Clin. Chem. Lab. Med. 2007; 45 (1): 30–34. DOI: 10.1515/CCLM.2007.025.Mroczko B., Groblewska M., Wereszczyńska-Siemiatkowska U., Okulczyk B., Kedra B., Łaszewicz W., Dabrowski A., Szmitkowski M. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin. Chim. Acta. 2007; 380 (1–2): 208–212. DOI: 10.1016/j.cca.2007.02.037.Mroczko B., Groblewska M., Wereszczyńska-Siemiatkowska U., Okulczyk B., Kedra B., Łaszewicz W., Dabrowski A., Szmitkowski M. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clin. Chim. Acta. 2007; 380 (1–2): 208–212. DOI: 10.1016/j.cca.2007.02.037.Zhu X.D., Zhang J.B., Zhuang P.Y., Zhu H.G., Zhang W., Xiong Y.Q., Wu W.Z., Wang L., Tang Z.Y., Sun H.C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008; 26 (16): 2707–2716. DOI: 10.1200/JCO.2007.15.6521.Zhu X.D., Zhang J.B., Zhuang P.Y., Zhu H.G., Zhang W., Xiong Y.Q., Wu W.Z., Wang L., Tang Z.Y., Sun H.C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008; 26 (16): 2707–2716. DOI: 10.1200/JCO.2007.15.6521.Smith H.O., Anderson P.S., Kuo D.Y., Goldberg G.L., DeVictoria C.L., Boocock C.A., Jones J.G., Runowicz C.D., Stanley E.R., Pollard J.W. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin. Cancer Res. 1995; 1 (3): 313–325.Smith H.O., Anderson P.S., Kuo D.Y., Goldberg G.L., DeVictoria C.L., Boocock C.A., Jones J.G., Runowicz C.D., Stanley E.R., Pollard J.W. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. Clin. Cancer Res. 1995; 1 (3): 313–325.Steiner J.L., Murphy E.A. Importance of chemokine (CC-motif) ligand 2 in breast cancer. The International Journal of Biological Markers. 2012; 27 (3): 179–185. DOI: 10.5301/JBM.2012.9345.Steiner J.L., Murphy E.A. Importance of chemokine (CC-motif) ligand 2 in breast cancer. The International Journal of Biological Markers. 2012; 27 (3): 179–185. DOI: 10.5301/JBM.2012.9345.Pienta K.J., Machiels J.P., Schrijvers D., Alekseev B., Shkolnik M., Crabb S.J., Li S., Seetharam S., Puchalski T.A., Takimoto C., Elsayed Y., Dawkins F., de Bono J.S. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013; 31 (3): 760–768. DOI: 10.1007/s10637-012-9869-8.Pienta K.J., Machiels J.P., Schrijvers D., Alekseev B., Shkolnik M., Crabb S.J., Li S., Seetharam S., Puchalski T.A., Takimoto C., Elsayed Y., Dawkins F., de Bono J.S. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013; 31 (3): 760–768. DOI: 10.1007/s10637-012-9869-8.Sandhu S.K., Papadopoulos K., Fong P.C., Patnaik A., Messiou C., Olmos D., Wang G., Tromp B.J., Puchalski T.A., Balkwill F., Berns B., Seetharam S., de Bono J.S., Tolcher A.W. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 2013; 71 (4): 1041–1050. DOI: 10.1007/s00280-013-2099-8.Sandhu S.K., Papadopoulos K., Fong P.C., Patnaik A., Messiou C., Olmos D., Wang G., Tromp B.J., Puchalski T.A., Balkwill F., Berns B., Seetharam S., de Bono J.S., Tolcher A.W. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother. Pharmacol. 2013; 71 (4): 1041–1050. DOI: 10.1007/s00280-013-2099-8.Brana I., Calles A., Lo Russo P.M., Yee L.K., Puchalski T.A., Seetharam S., Zhong B., de Boer C.J., Tabernero J., Calvo E. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015; 10 (1): 111–123. DOI: 10.1007/s11523-014-0320-2.Brana I., Calles A., Lo Russo P.M., Yee L.K., Puchalski T.A., Seetharam S., Zhong B., de Boer C.J., Tabernero J., Calvo E. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015; 10 (1): 111–123. DOI: 10.1007/s11523-014-0320-2.Bonapace L., Coissieux M.M., Wyckoff J., Mertz K.D., Varga Z., Junt T., Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014; 515 (7525): 130–133. DOI: 10.1038/nature13862.Bonapace L., Coissieux M.M., Wyckoff J., Mertz K.D., Varga Z., Junt T., Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014; 515 (7525): 130–133. DOI: 10.1038/nature13862.Feng A.L., Zhu J.K., Sun J.T., Yang M.X., Neckenig M.R., Wang X.W., Shao Q.Q., Song B.F., Yang Q.F., Kong B.H., Qu X. CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. Clin. Exp. Immunol. 2011; 164 (1): 57– 65. DOI:10.1111/j.1365-2249.2011.04321.Feng A.L., Zhu J.K., Sun J.T., Yang M.X., Neckenig M.R., Wang X.W., Shao Q.Q., Song B.F., Yang Q.F., Kong B.H., Qu X. CD16+ monocytes in breast cancer patients: expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. Clin. Exp. Immunol. 2011; 164 (1): 57– 65. DOI:10.1111/j.1365-2249.2011.04321.Jiang L., Jiang S., Situ D., Lin Y., Yang H., Li Y., Long H., Zhou Z.. Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma. Oncotarget. 2015; 6 (11): 9542– 9550. DOI: 10.18632/oncotarget.3283.Jiang L., Jiang S., Situ D., Lin Y., Yang H., Li Y., Long H., Zhou Z.. Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma. Oncotarget. 2015; 6 (11): 9542– 9550. DOI: 10.18632/oncotarget.3283.Huang S.H., Waldron J.N., Milosevic M., Shen X., Ringash J., Su J., Tong L., Perez-Ordonez B., Weinreb I., Bayley A.J., Kim J., Hope A., Cho B.C., Giuliani M., Razak A., Goldstein D., Shi W., Liu F.F., Xu W., O’Sullivan B. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015; 121 (4): 545–555. DOI: 10.1002/cncr.29100.Huang S.H., Waldron J.N., Milosevic M., Shen X., Ringash J., Su J., Tong L., Perez-Ordonez B., Weinreb I., Bayley A.J., Kim J., Hope A., Cho B.C., Giuliani M., Razak A., Goldstein D., Shi W., Liu F.F., Xu W., O’Sullivan B. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer. 2015; 121 (4): 545–555. DOI: 10.1002/cncr.29100.Passlick B., Ziegler-Heitbrock L. Identification and Characterization of a Novel Monocyte Subpopulation in Human peripheral blood. Blood. 1989; 74 (7): 2527–2534.Passlick B., Ziegler-Heitbrock L. Identification and Characterization of a Novel Monocyte Subpopulation in Human peripheral blood. Blood. 1989; 74 (7): 2527–2534.Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., Leenen P.J., Liu Y.J., MacPherson G., Randolph G.J., Scherberich J., Schmitz J., Shortman K., Sozzani S., Strobl H., Zembala M., Austyn J.M., Lutz M.B. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116 (16): 74–80. DOI: 10.1182/blood-2010-02-258558.Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., Leenen P.J., Liu Y.J., MacPherson G., Randolph G.J., Scherberich J., Schmitz J., Shortman K., Sozzani S., Strobl H., Zembala M., Austyn J.M., Lutz M.B. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010; 116 (16): 74–80. DOI: 10.1182/blood-2010-02-258558.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–455. DOI: 10.1038/nature12034.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–455. DOI: 10.1038/nature12034.Fingerle G., Pforte A., Passlick B., Blumenstein M., Strö- bel M., Ziegler-Heitbrock L. The novel subset of CD14+/ CD16+ blood monocytesis expanded in sepsis patients. Blood. 1993; 82 (10): 3170–3176.Fingerle G., Pforte A., Passlick B., Blumenstein M., Strö- bel M., Ziegler-Heitbrock L. The novel subset of CD14+/ CD16+ blood monocytesis expanded in sepsis patients. Blood. 1993; 82 (10): 3170–3176.Fingerle-Rowso G., Auers J., Kreuzer E., Fraunberger P., Blumenstein M., Ziegler-Heitbrock L. Expansion of CD14+CD16+monocytes in critically ill cardiac surgery patients. Inflammation. 1998; 22 (8): 367–379. DOI: 10.1023/A:1022316815196.Fingerle-Rowso G., Auers J., Kreuzer E., Fraunberger P., Blumenstein M., Ziegler-Heitbrock L. Expansion of CD14+CD16+monocytes in critically ill cardiac surgery patients. Inflammation. 1998; 22 (8): 367–379. DOI: 10.1023/A:1022316815196.Ziegler-Heitbrock L. Monocyte subsets in man and other species. Cell Immunol. 2014; 289 (1–2): 135–139. DOI: 10.1016/j.cellimm.2014.03.019.Ziegler-Heitbrock L. Monocyte subsets in man and other species. Cell Immunol. 2014; 289 (1–2): 135–139. DOI: 10.1016/j.cellimm.2014.03.019.Gordon S. and Taylor P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005; 5 (12): 953– 964. DOI: 10.1038/nri1733.Gordon S. and Taylor P. R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005; 5 (12): 953– 964. DOI: 10.1038/nri1733.Ginhoux F. and Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 2014; 14 (6): 392–404. DOI: 10.1038/nri3671.Ginhoux F. and Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat. Rev. Immunol. 2014; 14 (6): 392–404. DOI: 10.1038/nri3671.Cross J. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors. Immunity. 2010; 33 (3): 375–386. DOI: 10.1016/j.immuni.2010.08.012.Cross J. Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors. Immunity. 2010; 33 (3): 375–386. DOI: 10.1016/j.immuni.2010.08.012.Zawada A.M., Rogacev K.S., Rotter B., Winter P., Marell R.R., Fliser D., Heine G.H. SuperSAGE evidence for CD14+CD16+ monocytes as a third monocyte subset. Blood. 2011; 118 (12): 50–61. DOI: 10.1182/blood-2011-01-326827.Zawada A.M., Rogacev K.S., Rotter B., Winter P., Marell R.R., Fliser D., Heine G.H. SuperSAGE evidence for CD14+CD16+ monocytes as a third monocyte subset. Blood. 2011; 118 (12): 50–61. DOI: 10.1182/blood-2011-01-326827.Gratchev A., Ovsiy I., Manousaridis I., Riabov V., Orekhov A., Kzhyshkowska J. Novel monocyte biomarkers of atherogenic conditions. Curr. Pharm. Des. 2013; 19 (33): 5859–5864. DOI: 10.2174/1381612811319330004.Gratchev A., Ovsiy I., Manousaridis I., Riabov V., Orekhov A., Kzhyshkowska J. Novel monocyte biomarkers of atherogenic conditions. Curr. Pharm. Des. 2013; 19 (33): 5859–5864. DOI: 10.2174/1381612811319330004.Wong K.L., Tai J.J., Wong W.C., Han H., Sem X., Yeap W.H., Kourilsky P., Wong S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011; 118 (5): 16–31. DOI: 10.1182/blood-2010-12-326355.Wong K.L., Tai J.J., Wong W.C., Han H., Sem X., Yeap W.H., Kourilsky P., Wong S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood. 2011; 118 (5): 16–31. DOI: 10.1182/blood-2010-12-326355.Saleh M.N., Goldman S.J., Lo Buglio A.F., Beall A.C., Sabio H., McCord M.C., Minasian L., Alpaugh R.K., Weiner L.M., Munn D.H. CD16 + monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood. 1995; 85 (10): 2910–2917.Saleh M.N., Goldman S.J., Lo Buglio A.F., Beall A.C., Sabio H., McCord M.C., Minasian L., Alpaugh R.K., Weiner L.M., Munn D.H. CD16 + monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood. 1995; 85 (10): 2910–2917.Schauer D., Starlinger P., Reiter C., Jahn N., Zajc P., Buchberger E., Bachleitner-Hofmann T., Bergmann M., Stift A., Gruenberger T., Brostjan C. Intermediate monocytes but not TIE2- expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One. 2012; 7 (9): e44450. DOI: 10.1371/journal.pone.0044450.Schauer D., Starlinger P., Reiter C., Jahn N., Zajc P., Buchberger E., Bachleitner-Hofmann T., Bergmann M., Stift A., Gruenberger T., Brostjan C. Intermediate monocytes but not TIE2- expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One. 2012; 7 (9): e44450. DOI: 10.1371/journal.pone.0044450.Subimerb C., Pinlaor S., Lulitanond V., Khuntikeo N., Okada S., McGrath M.S., Wongkham S. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin. Exp. Immunol. 2010; 161 (3): 471–479. DOI: 10.1111/j.1365- 2249.2010.04200.Subimerb C., Pinlaor S., Lulitanond V., Khuntikeo N., Okada S., McGrath M.S., Wongkham S. Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. Clin. Exp. Immunol. 2010; 161 (3): 471–479. DOI: 10.1111/j.1365- 2249.2010.04200.Hamm A., Prenen H., Van Delm W., Di Matteo M., Wenes M., Delamarre E., Schmidt T., Weitz J., Sarmiento R., Dezi A., Gasparini G., Rothé F., Schmitz R., D’Hoore A., Iserentant H., Hendlisz A., Mazzone M. Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut. 2016; 65 (6): 990–1000. DOI: 10.1136/gutjnl-2014-308988.Hamm A., Prenen H., Van Delm W., Di Matteo M., Wenes M., Delamarre E., Schmidt T., Weitz J., Sarmiento R., Dezi A., Gasparini G., Rothé F., Schmitz R., D’Hoore A., Iserentant H., Hendlisz A., Mazzone M. Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. Gut. 2016; 65 (6): 990–1000. DOI: 10.1136/gutjnl-2014-308988.Grage-Griebenow E., Zawatzky R., Kahlert H., Brade L., Flad H., Ernst M. Identification of a novel dendritic cell-like subset of CD64+/CD16+ blood monocytes. Eur. J. Immunol. 2001; 31 (1): 48–56. DOI: 10.1002/1521-4141(200101)31:1<48::AID-IMMU48>3.0.CO;2-5Grage-Griebenow E., Zawatzky R., Kahlert H., Brade L., Flad H., Ernst M. Identification of a novel dendritic cell-like subset of CD64+/CD16+ blood monocytes. Eur. J. Immunol. 2001; 31 (1): 48–56. DOI: 10.1002/1521-4141(200101)31:1<48::AID-IMMU48>3.0.CO;2-5Turrini R., Pabois A., Xenarios I., Coukos G., Delaloye J.F., Doucey M.A. TIE-2 expressing monocytes in human cancers. Oncoimmunology. 2017; 6 (4): e1303585. DOI: 10.1080/2162402X.2017.1303585.Turrini R., Pabois A., Xenarios I., Coukos G., Delaloye J.F., Doucey M.A. TIE-2 expressing monocytes in human cancers. Oncoimmunology. 2017; 6 (4): e1303585. DOI: 10.1080/2162402X.2017.1303585.Welford A.F., Biziato D., Coffelt S.B., Nucera S., Fisher M., Pucci F., Di Serio C., Naldini L., De Palma M., Tozer G.M., Lewis C.E. TIE2-expressing macrophages limit the therapeutic efficacy of the vasculardisrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011; 121 (5): 1969–1973. DOI: 10.1172/JCI44562.Welford A.F., Biziato D., Coffelt S.B., Nucera S., Fisher M., Pucci F., Di Serio C., Naldini L., De Palma M., Tozer G.M., Lewis C.E. TIE2-expressing macrophages limit the therapeutic efficacy of the vasculardisrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011; 121 (5): 1969–1973. DOI: 10.1172/JCI44562.Guex N., Crespo I., Bron S., Ifticene-Treboux A., FaesVan’t Hull E., Kharoubi S., Liechti R., Werffeli P., Ibberson M., Majo F., Nicolas M., Laurent J., Garg A., Zaman K., Lehr H.A., Stevenson B.J., Rüegg C., Coukos G., Delaloye J.F., Xenarios I., Doucey M.A. Angiogenic activity of breast cancer patients’ monocytes reverted by combined use of systems modeling and experimental approaches. PLoS Comput Biol. 2015; Mar. 13; 11 (3): e1004050. DOI: 10.1371/journal.pcbi.1004050.Guex N., Crespo I., Bron S., Ifticene-Treboux A., FaesVan’t Hull E., Kharoubi S., Liechti R., Werffeli P., Ibberson M., Majo F., Nicolas M., Laurent J., Garg A., Zaman K., Lehr H.A., Stevenson B.J., Rüegg C., Coukos G., Delaloye J.F., Xenarios I., Doucey M.A. Angiogenic activity of breast cancer patients’ monocytes reverted by combined use of systems modeling and experimental approaches. PLoS Comput Biol. 2015; Mar. 13; 11 (3): e1004050. DOI: 10.1371/journal.pcbi.1004050.Forget M.A., Voorhees J.L., Cole S.L., Dakhlallah D., Patterson I.L., Gross A.C., Moldovan L., Mo X., Evans R., Marsh C.B. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS One. 2014; 9 (6): e98623. DOI: 10.1371/journal.pone.0098623.Forget M.A., Voorhees J.L., Cole S.L., Dakhlallah D., Patterson I.L., Gross A.C., Moldovan L., Mo X., Evans R., Marsh C.B. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS One. 2014; 9 (6): e98623. DOI: 10.1371/journal.pone.0098623.Ibberson M., Bron S., Guex N., Faes-van’t Hull E., Ifticene-Treboux A., Henry L., Lehr H.A., Delaloye J.F., Coukos G., Xenarios I. TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors. Clin. Cancer. Res. 2013; 19 (13): 3439–3449. DOI: 10.1158/1078-0432.CCR-12-3181.Ibberson M., Bron S., Guex N., Faes-van’t Hull E., Ifticene-Treboux A., Henry L., Lehr H.A., Delaloye J.F., Coukos G., Xenarios I. TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors. Clin. Cancer. Res. 2013; 19 (13): 3439–3449. DOI: 10.1158/1078-0432.CCR-12-3181.Pulaski H.L., Spahlinger G., Silva I.A., McLean K., Kueck A.S., Reynolds R.K., Coukos G., Conejo-Garcia J.R., Buckanovich R.J. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J. Transl. Med. 2009; Jun. 19; 7 (1): 49. DOI: 10.1186/1479-5876-7-49.Pulaski H.L., Spahlinger G., Silva I.A., McLean K., Kueck A.S., Reynolds R.K., Coukos G., Conejo-Garcia J.R., Buckanovich R.J. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J. Transl. Med. 2009; Jun. 19; 7 (1): 49. DOI: 10.1186/1479-5876-7-49.Bron S., Henry L., Faes-van’t Hull E., Turrini R., Vanhecke D., Guex N., Ifticene-Treboux A., Iancu E.M., Semilietof A., Rufer N., Lehr H.-A., Xenarios I., Coukos G., Delaloye J.F., Doucey M.A. TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. Oncoimmunology. 2016; 5 (2): e1073882. DOI: 10.1080/2162402X.2015.1073882.Bron S., Henry L., Faes-van’t Hull E., Turrini R., Vanhecke D., Guex N., Ifticene-Treboux A., Iancu E.M., Semilietof A., Rufer N., Lehr H.-A., Xenarios I., Coukos G., Delaloye J.F., Doucey M.A. TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. Oncoimmunology. 2016; 5 (2): e1073882. DOI: 10.1080/2162402X.2015.1073882.Tsutsui S., Inoue H., Yasuda K., Suzuki K., Takeuchi H., Nishizaki T., Higashi H., Era S., Mori M. Angiopoietin-2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res. Treat. 2006; 98 (3): 261–266. DOI: 10.1007/s10549-005-9157-9.Tsutsui S., Inoue H., Yasuda K., Suzuki K., Takeuchi H., Nishizaki T., Higashi H., Era S., Mori M. Angiopoietin-2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res. Treat. 2006; 98 (3): 261–266. DOI: 10.1007/s10549-005-9157-9.Ji J., Zhang G., Sun B., Yuan H., Huang Y., Zhang J, Wei X., Zhang X., Hou J. The frequency of tumor-infiltrating Tie-2-expressing monocytes in renal cell carcinoma: its relationship to angiogenesis and progression. Urology. 2013; 82 (4): e9–13. DOI: 10.1016/j.urology.2013.05.026.Ji J., Zhang G., Sun B., Yuan H., Huang Y., Zhang J, Wei X., Zhang X., Hou J. The frequency of tumor-infiltrating Tie-2-expressing monocytes in renal cell carcinoma: its relationship to angiogenesis and progression. Urology. 2013; 82 (4): e9–13. DOI: 10.1016/j.urology.2013.05.026.Schauer D., Starlinger P., Reiter C., Jahn N., Zajc P., Buchberger E., Bachleitner-Hofmann T., Bergmann M., Stift A., Gruenberger T., Brostjan C. Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer. PLoS One. 2012; 7 (9): e44450. DOI: 10.1371/journal.pone.0044450.Schauer D., Starlinger P., Reiter C., Jahn N., Zajc P., Buchberger E., Bachleitner-Hofmann T., Bergmann M., Stift A., Gruenberger T., Brostjan C. Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer. PLoS One. 2012; 7 (9): e44450. DOI: 10.1371/journal.pone.0044450.Gabrusiewicz K., Liu D., Cortes-Santiago N., Hossain M.B., Conrad C.A., Aldape K.D., Fuller G.N., Marini F.C., Alonso M.M., Idoate M.A., Gilbert M.R., Fueyo J., Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014; 5 (8): 2208–2220. DOI: 10.18632/oncotarget.1893.Gabrusiewicz K., Liu D., Cortes-Santiago N., Hossain M.B., Conrad C.A., Aldape K.D., Fuller G.N., Marini F.C., Alonso M.M., Idoate M.A., Gilbert M.R., Fueyo J., Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget. 2014; 5 (8): 2208–2220. DOI: 10.18632/oncotarget.1893.Venneri M.A., De Palma M., Ponzoni M., Pucci F., Scielzo C., Zonari E., Mazzieri R., Doglioni C., Naldini L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007; 109 (12): 5276–5285. DOI: 10.1182/blood-2006-10-053504.Venneri M.A., De Palma M., Ponzoni M., Pucci F., Scielzo C., Zonari E., Mazzieri R., Doglioni C., Naldini L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007; 109 (12): 5276–5285. DOI: 10.1182/blood-2006-10-053504.Goede V., Coutelle O., Shimabukuro-Vornhagen A., Holtick U., Neuneier J., Koslowsky T.C., Weihrauch M.R., von Bergwelt-Baildon M., Hacker U.T. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest. 2012; 30 (3): 225–230. DOI: 10.3109/07357907.2011.636114.Goede V., Coutelle O., Shimabukuro-Vornhagen A., Holtick U., Neuneier J., Koslowsky T.C., Weihrauch M.R., von Bergwelt-Baildon M., Hacker U.T. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest. 2012; 30 (3): 225–230. DOI: 10.3109/07357907.2011.636114.De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007; 28 (12): 519–524. DOI: 10.1016/j.it.2007.09.004.De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007; 28 (12): 519–524. DOI: 10.1016/j.it.2007.09.004.Sainz B.J., Carron E., Vallespinуs M., Machado H.L. Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies. Mediators Inflamm. 2016; 2016: 1–15. DOI: 10.1155/2016/9012369.Sainz B.J., Carron E., Vallespinуs M., Machado H.L. Cancer stem cells and macrophages: implications in tumor biology and therapeutic strategies. Mediators Inflamm. 2016; 2016: 1–15. DOI: 10.1155/2016/9012369.Gasteiger G., D’Osualdo A., Schubert D.A., Weber A., Bruscia E.M., Hartl D. Cellular Innate Immunity: An old game with new players. J. Innate Immun. 2017; 9 (2): 111–125. DOI: 10.1159/000453397.Gasteiger G., D’Osualdo A., Schubert D.A., Weber A., Bruscia E.M., Hartl D. Cellular Innate Immunity: An old game with new players. J. Innate Immun. 2017; 9 (2): 111–125. DOI: 10.1159/000453397.Saeed S., Quintin J., Kerstens H.H., Rao N.A., Aghajanirefah A., Matarese F., Cheng S.C., Ratter J., Berentsen K., van der Ent M.A., Sharifi N., Janssen-Megens E.M., Ter Huurne M., Mandoli A., van Schaik T., Ng A., Burden F., Downes K., Frontini M., Kumar V., Giamarellos-Bourboulis E.J., Ouwehand W.H., van der Meer J.W., Joosten L.A., Wijmenga C., Martens J.H., Xavier R.J., Logie C., Netea M.G., Stunnenberg H.G. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014; 345 (6204): 1251086. DOI: 10.1126/science.1251086.Saeed S., Quintin J., Kerstens H.H., Rao N.A., Aghajanirefah A., Matarese F., Cheng S.C., Ratter J., Berentsen K., van der Ent M.A., Sharifi N., Janssen-Megens E.M., Ter Huurne M., Mandoli A., van Schaik T., Ng A., Burden F., Downes K., Frontini M., Kumar V., Giamarellos-Bourboulis E.J., Ouwehand W.H., van der Meer J.W., Joosten L.A., Wijmenga C., Martens J.H., Xavier R.J., Logie C., Netea M.G., Stunnenberg H.G. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014; 345 (6204): 1251086. DOI: 10.1126/science.1251086.Hoeksema M.A., de Winther M.P. Epigenetic regulation of monocyte and macrophage function. Antioxid Redox Signal. 2016; 25 (14): 758–774. DOI: 10.1089/ars.2016.6695.Hoeksema M.A., de Winther M.P. Epigenetic regulation of monocyte and macrophage function. Antioxid Redox Signal. 2016; 25 (14): 758–774. DOI: 10.1089/ars.2016.6695.Netea M.G., Joosten L.A., Latz E., Mills K.H., Natoli G., Stunnenberg H.G., O’Neill L.A., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352 (6284): aaf1098. DOI: 10.1126/science.aaf1098.Netea M.G., Joosten L.A., Latz E., Mills K.H., Natoli G., Stunnenberg H.G., O’Neill L.A., Xavier R.J. Trained immunity: A program of innate immune memory in health and disease. Science. 2016; 352 (6284): aaf1098. DOI: 10.1126/science.aaf1098.Bekkering S., Joosten L.A., van der Meer J.W., Netea M.G., Riksen N.P. The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. Clin. Ther. 2015; 37 (4): 914–923. DOI: 10.1016/j.clinthera.2015.01.008.Bekkering S., Joosten L.A., van der Meer J.W., Netea M.G., Riksen N.P. The epigenetic memory of monocytes and macrophages as a novel drug target in atherosclerosis. Clin. Ther. 2015; 37 (4): 914–923. DOI: 10.1016/j.clinthera.2015.01.008.van Diepen J.A., Thiem K., Stienstra R., Riksen N.P., Tack C.J., Netea M.G. Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive? Cell Mol. Life Sci. 2016; 73 (24): 4675–4684. DOI: 10.1007/s00018-016-2316-9.van Diepen J.A., Thiem K., Stienstra R., Riksen N.P., Tack C.J., Netea M.G. Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive? Cell Mol. Life Sci. 2016; 73 (24): 4675–4684. DOI: 10.1007/s00018-016-2316-9.Almatroodi S.A., McDonald C.F., Collins A.L., Darby I.A., Pouniotis D.S. Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer. World J. Clin. Oncol. 2014; 5 (5): 1078–1087. DOI: 10.5306/wjco.v5.i5.1078.Almatroodi S.A., McDonald C.F., Collins A.L., Darby I.A., Pouniotis D.S. Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer. World J. Clin. Oncol. 2014; 5 (5): 1078–1087. DOI: 10.5306/wjco.v5.i5.1078.Hanna R.N., Cekic C., Sag D., Tacke R., Thomas G.D., Nowyhed H., Herrley E., Rasquinha N., McArdle S., Wu R., Peluso E., Metzger D., Ichinose H., Shaked I., Chodaczek G., Biswas S.K., Hedrick C.C. Patrolling monocytes control tumor metastasis to the lung. Science. 2015; 350 (6263): 985–990. DOI: 10.1126/science.aac9407.Hanna R.N., Cekic C., Sag D., Tacke R., Thomas G.D., Nowyhed H., Herrley E., Rasquinha N., McArdle S., Wu R., Peluso E., Metzger D., Ichinose H., Shaked I., Chodaczek G., Biswas S.K., Hedrick C.C. Patrolling monocytes control tumor metastasis to the lung. Science. 2015; 350 (6263): 985–990. DOI: 10.1126/science.aac9407.Zhang B., Cao M., He Y., Liu Y., Zhang G., Yang C., Du Y., Xu J., Hu J., Gao F. Increased circulating M2- like monocytes in patients with breast cancer. Tumour Biol. 2017; 39 (6): 1010428317711571. DOI: 10.1177/1010428317711571.Zhang B., Cao M., He Y., Liu Y., Zhang G., Yang C., Du Y., Xu J., Hu J., Gao F. Increased circulating M2- like monocytes in patients with breast cancer. Tumour Biol. 2017; 39 (6): 1010428317711571. DOI: 10.1177/1010428317711571.Adams D.L., Martin S.S., Alpaugh R.K., Charpentier M., Tsai S., Bergan R.C., Ogden I.M., Catalona W., Chumsri S., Tang C.M., Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences. 2014; 111 (9): 3514–3519. DOI: 10.1073/pnas.1320198111.Adams D.L., Martin S.S., Alpaugh R.K., Charpentier M., Tsai S., Bergan R.C., Ogden I.M., Catalona W., Chumsri S., Tang C.M., Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences. 2014; 111 (9): 3514–3519. DOI: 10.1073/pnas.1320198111.Adams D.L., Adams D.K., Alpaugh R.K., Cristofanilli M., Martin S.S., Chumsri S., Tang C.M., Marks J.R. Circulating cancer-associated macrophage-like cells differentiate malignant breast cancer and benign breast conditions. Cancer Epidemiol. Biomarkers Prev. 2016; 25 (7): 1037– 1042. DOI: 10.1158/1055-9965.Adams D.L., Adams D.K., Alpaugh R.K., Cristofanilli M., Martin S.S., Chumsri S., Tang C.M., Marks J.R. Circulating cancer-associated macrophage-like cells differentiate malignant breast cancer and benign breast conditions. Cancer Epidemiol. Biomarkers Prev. 2016; 25 (7): 1037– 1042. DOI: 10.1158/1055-9965.Biswas S.K., Mantovani A. Macrophages: biology and role in the pathology of diseases. New York: Springer, 2014: 7–11. DOI: 10.1007/978-1-4939-1311-4.Biswas S.K., Mantovani A. Macrophages: biology and role in the pathology of diseases. New York: Springer, 2014: 7–11. DOI: 10.1007/978-1-4939-1311-4.Zhao L., Shao Q., Zhang Y., Zhang L., He Y., Wang L., Kong B., Qu X. Human monocytes undergo functional re-programming during differentiation to dendritic cell mediated by human extravillous trophoblasts. Sci. Rep. 2016; 6 (1): 20409. DOI: 10.1038/srep20409.Zhao L., Shao Q., Zhang Y., Zhang L., He Y., Wang L., Kong B., Qu X. Human monocytes undergo functional re-programming during differentiation to dendritic cell mediated by human extravillous trophoblasts. Sci. Rep. 2016; 6 (1): 20409. DOI: 10.1038/srep20409.Baj-Krzyworzeka M., Baran J., Szatanek R., Mytar B., Siedlar M., Zembala M. Interactions of human monocytes with TMVs (tumour-derived microvesicles). Biochem. Soc. Trans. 2013; 41 (1): 268–272. DOI: 10.1042/BST20120244.Baj-Krzyworzeka M., Baran J., Szatanek R., Mytar B., Siedlar M., Zembala M. Interactions of human monocytes with TMVs (tumour-derived microvesicles). Biochem. Soc. Trans. 2013; 41 (1): 268–272. DOI: 10.1042/BST20120244.Dimitrov S., Shaikh F., Pruitt C., Green M., Wilson K., Beg N., Hong S. Differential TNF production by monocyte subsets under physical stress: blunted mobilization of proinflammatory monocytes in prehypertensive individuals. Brain Behav. Immun. 2013; 27 (1): 101–108. DOI: 10.1016/j.bbi.2012.10.003.Dimitrov S., Shaikh F., Pruitt C., Green M., Wilson K., Beg N., Hong S. Differential TNF production by monocyte subsets under physical stress: blunted mobilization of proinflammatory monocytes in prehypertensive individuals. Brain Behav. Immun. 2013; 27 (1): 101–108. DOI: 10.1016/j.bbi.2012.10.003.van Furth R., Cohn Z.A., Hirsch J.G., Humphrey J.H., Spector W.G., Langevoort H.L. Mononuclear phagocytic system: new classification of macrophages, monocytes and of their cell line. Bull World Health Organ. 1972; 47: 651–658.van Furth R., Cohn Z.A., Hirsch J.G., Humphrey J.H., Spector W.G., Langevoort H.L. Mononuclear phagocytic system: new classification of macrophages, monocytes and of their cell line. Bull World Health Organ. 1972; 47: 651–658.Guilliams M., van de Laar L.. A hitchhiker’s guide to myeloid cell subsets: practical implementation of a novel mononuclear phagocyte classification system. Front. Immunol. 2015; 6. DOI: 10.3389/fimmu.2015.00406.Guilliams M., van de Laar L.. A hitchhiker’s guide to myeloid cell subsets: practical implementation of a novel mononuclear phagocyte classification system. Front. Immunol. 2015; 6. DOI: 10.3389/fimmu.2015.00406.Чердынцева Н.В., Митрофанова И.В., Булдаков М.А., Стахеева М.Н., Патышева М.Р., Завьялова М.В., Кжышковска Ю.Г. Макрофаги и опухолевая прогрессия: на пути к макрофаг-специфичной терапии. юллетень сибирской медицины. 2017; 16 (4): 61–74. DOI: 10.20538/1682-0363-2017-4-61-74.Cherdyntseva N.V., Mitrofanova I.V., Buldakov M.A., Stakheeva M.N., Patysheva M.R., Zavjalova M.V., Kzhyshkowska J.G. Macrophages and tumor progression: on the way to macrophage-specific therapy. Bulletin of Siberian Medicine. 2017; 16 (4): 61–74 (in Russ.). DOI: 10.20538/1682-0363-2017-4-61-74.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–455. DOI: 10.1038/nature12034.Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature. 2013; 496 (7446): 445–455. DOI: 10.1038/nature12034.Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van den Bossche J., Mack M., Pipeleers D., In’t Veld P., e Baetselier P. Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010; 70 (14): 5728–5739. DOI: 10.1158/0008-5472.CAN-09-4672.Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van den Bossche J., Mack M., Pipeleers D., In’t Veld P., e Baetselier P. Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010; 70 (14): 5728–5739. DOI: 10.1158/0008-5472.CAN-09-4672.Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., Pamer E.G., Li M.O. The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344 (6186): 921–925. DOI: 10.1126/science.1252510.Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., Pamer E.G., Li M.O. The cellular and molecular origin of tumor-associated macrophages. Science. 2014; 344 (6186): 921–925. DOI: 10.1126/science.1252510.Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475 (7355): 222–225. DOI: 10.1038/nature10138.Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011; 475 (7355): 222–225. DOI: 10.1038/nature10138.Shand F.H., Ueha S., Otsuji M., Koid S.S., Shichino S., Tsukui T., Kosugi-Kanaya M., Abe J., Tomura M., Ziogas J., Matsushima K. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proceedings of the National Academy of Sciences. 2014; 111 (21): 7771–7776. DOI: 10.1073/pnas.1402914111.Shand F.H., Ueha S., Otsuji M., Koid S.S., Shichino S., Tsukui T., Kosugi-Kanaya M., Abe J., Tomura M., Ziogas J., Matsushima K. Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proceedings of the National Academy of Sciences. 2014; 111 (21): 7771–7776. DOI: 10.1073/pnas.1402914111.Harney A.S., Arwert E.N., Entenberg D., Wang Y., Guo P., Qian B.Z., Oktay M.H., Pollard J.W., Jones J.G., Condeelis J.S. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 2015; 5 (9): 932–943. DOI: 10.1158/2159-8290.CD-15-0012.Harney A.S., Arwert E.N., Entenberg D., Wang Y., Guo P., Qian B.Z., Oktay M.H., Pollard J.W., Jones J.G., Condeelis J.S. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov. 2015; 5 (9): 932–943. DOI: 10.1158/2159-8290.CD-15-0012.Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008; 111 (12): 5457–5466. DOI: 10.1182/blood-2008-01-136895.Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008; 111 (12): 5457–5466. DOI: 10.1182/blood-2008-01-136895.Bögels M., Braster R., Nijland P.G., Gül N., van de Luijtgaarden W., Fijneman R.J., Meijer G.A., Jimenez C.R., Beelen R.H., van Egmond M. Carcinoma origin dictates differential skewing of monocyte function. OncoImmunology. 2012; 1 (6): 798–809. DOI: 10.4161/onci.20427.Bögels M., Braster R., Nijland P.G., Gül N., van de Luijtgaarden W., Fijneman R.J., Meijer G.A., Jimenez C.R., Beelen R.H., van Egmond M. Carcinoma origin dictates differential skewing of monocyte function. OncoImmunology. 2012; 1 (6): 798–809. DOI: 10.4161/onci.20427.Baron S., Finbloom J., Horowitz J., Bekisz J., Morrow A., Zhao T., Fey S., Schmeisser H., Balinsky C., Miyake K., Clark C., Zoon K. Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro. J. Interferon. Cytokine Res. 2011; 31 (7): 569–573. DOI: 10.1089/jir.2010.0153.Baron S., Finbloom J., Horowitz J., Bekisz J., Morrow A., Zhao T., Fey S., Schmeisser H., Balinsky C., Miyake K., Clark C., Zoon K. Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro. J. Interferon. Cytokine Res. 2011; 31 (7): 569–573. DOI: 10.1089/jir.2010.0153.Кжышковска Ю.Г., Митрофанова И.В., Завьялова М.В., Слонимская Е.М., Чердынцева Н.В. Опухолеассоциированные макрофаги. М.: Наука, 2017: 224.Kzhyshkowska J.G., Mitrofanova I.V., Zavyalova M.V., Slonimskaya E.M., Cherdyntseva N.V. Tumor-associated macrophages. Moscow: Nauka Publ., 2017: 224 (in Russ).Hettinger J., Richards D.M., Hansson J., Barra M.M., Joschko A.C., Krijgsveld J., Feuerer M. Origin of monocytes and macrophages in a committed progenitor. Nat. Immunl. 2013; 14 (8): 821–830. DOI: 10.1038/ni.2638.Hettinger J., Richards D.M., Hansson J., Barra M.M., Joschko A.C., Krijgsveld J., Feuerer M. Origin of monocytes and macrophages in a committed progenitor. Nat. Immunl. 2013; 14 (8): 821–830. DOI: 10.1038/ni.2638.Segura E., Amigorena S. Inflammatory dendritic cells in mice and humans. Trends immunol. 2013; 34 (9): 440– 445. DOI: 10.1016/j.it.2013.06.001.Segura E., Amigorena S. Inflammatory dendritic cells in mice and humans. Trends immunol. 2013; 34 (9): 440– 445. DOI: 10.1016/j.it.2013.06.001.Maeng H., Terabe M., Berzofsky J.A. Cancer vaccines: translation from mice to human clinical trials. Curr. Opin Immunol. 2018; 51: 111–122. DOI: 10.1016/j.coi.2018.03.001.Maeng H., Terabe M., Berzofsky J.A. Cancer vaccines: translation from mice to human clinical trials. Curr. Opin Immunol. 2018; 51: 111–122. DOI: 10.1016/j.coi.2018.03.001.Kongsted P., Borch T.H., Ellebaek E., Iversen T.Z., Andersen R., Met Ö., Hansen M., Lindberg H., Sengeløv L., Svane I.M. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. Cytotherapy. 2017; 19 (4): 500–513. DOI: 10.1016/j.jcyt.2017.01.007.Kongsted P., Borch T.H., Ellebaek E., Iversen T.Z., Andersen R., Met Ö., Hansen M., Lindberg H., Sengeløv L., Svane I.M. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study. Cytotherapy. 2017; 19 (4): 500–513. DOI: 10.1016/j.jcyt.2017.01.007.Vuk-Pavlović S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., Dietz A.B. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate. 2010; 70 (4): 443–455. DOI: 10.1002/pros.21078.Vuk-Pavlović S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., Dietz A.B. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate. 2010; 70 (4): 443–455. DOI: 10.1002/pros.21078.Laborde R.R., Lin Y., Gustafson M.P., Bulur P.A., Dietz A.B. Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells): the gateway to improved responses. Frontiers in Immunology. 2014; 5: 147. DOI: 10.3389/fimmu.2014.00147.Laborde R.R., Lin Y., Gustafson M.P., Bulur P.A., Dietz A.B. Cancer vaccines in the world of immune suppressive monocytes (CD14+HLA-DRlo/neg cells): the gateway to improved responses. Frontiers in Immunology. 2014; 5: 147. DOI: 10.3389/fimmu.2014.00147.Yu J., Du W., Yan F., Wang Y., Li H., Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013; 190 (7): 3783–3797. DOI:10.4049/jimmunol.1201449.Yu J., Du W., Yan F., Wang Y., Li H., Cao S, Yu W, Shen C, Liu J, Ren X. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013; 190 (7): 3783–3797. DOI:10.4049/jimmunol.1201449.Mougiakakos D., Jitschin R., von Bahr L., Poschke I., Gary R., Sundberg B., Gerbitz A, Ljungman P, Le Blanc K. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013; 27 (2): 377–388. DOI: 10.1038/leu.2012.215.Mougiakakos D., Jitschin R., von Bahr L., Poschke I., Gary R., Sundberg B., Gerbitz A, Ljungman P, Le Blanc K. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia. 2013; 27 (2): 377–388. DOI: 10.1038/leu.2012.215.Maeda A., Kawamura T., Ueno T., Usui N., Miyagawa S. Monocytic suppressor cells derived from human peripheral blood suppress xenogenic immune reactions. Xenotransplantation. 2014; 21 (1): 46–56. DOI: 10.1111/xen.12067.Maeda A., Kawamura T., Ueno T., Usui N., Miyagawa S. Monocytic suppressor cells derived from human peripheral blood suppress xenogenic immune reactions. Xenotransplantation. 2014; 21 (1): 46–56. DOI: 10.1111/xen.12067.Poschke I., Mao Y., Adamson L., Salazar-Onfray F., Masucci G., Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol. Immunother. 2012; 61 (6): 827–838. DOI: 10.1007/s00262-011-1143-y.Poschke I., Mao Y., Adamson L., Salazar-Onfray F., Masucci G., Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol. Immunother. 2012; 61 (6): 827–838. DOI: 10.1007/s00262-011-1143-y.Gustafson M.P., Lin Y., New K.C., Bulur P.A., O’Neill B.P., Gastineau D.A., Dietz AB. Systemic immune suppression in glioblastoma: the interplay between CD14+HLADRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010; 12 (7): 631–644. DOI:10.1093/neuonc/noq001.Gustafson M.P., Lin Y., New K.C., Bulur P.A., O’Neill B.P., Gastineau D.A., Dietz AB. Systemic immune suppression in glioblastoma: the interplay between CD14+HLADRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol. 2010; 12 (7): 631–644. DOI:10.1093/neuonc/noq001.Engblom C., Pfirschke C., Pittet M.J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer. 2016; 16 (7): 447–462. DOI: 10.1038/nrc.2016.54.Engblom C., Pfirschke C., Pittet M.J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer. 2016; 16 (7): 447–462. DOI: 10.1038/nrc.2016.54.Bonapace L., Coissieux M.M., Wyckoff J., Mertz K.D., Varga Z., Junt T., Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014; 515 (7525): 130–133. DOI: 10.1038/nature13862.Bonapace L., Coissieux M.M., Wyckoff J., Mertz K.D., Varga Z., Junt T., Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature. 2014; 515 (7525): 130–133. DOI: 10.1038/nature13862.Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., Erba E., Uboldi S., Zucchetti M., Pasqualini F. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013; 23 (2): 249–262. DOI: 10.1016/j.ccr.2013.01.008.Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., Erba E., Uboldi S., Zucchetti M., Pasqualini F. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013; 23 (2): 249–262. DOI: 10.1016/j.ccr.2013.01.008.

The authors declare that there are no conflicts of interest present.